Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 6/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ACP1 | P24666 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL680853 | 0.74 | NPC1 (0.45) | NPC1RAB9ASMN1; SMN2LMNAMAPT | |
| SCHEMBL2974783 | 0.72 | CDK8 (0.47) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| Hydrochloric Acid SCHEMBL4456673 | 0.72 | NPC1 (0.44) | NPC1RAB9ASMN1; SMN2LMNAMAPT | |
| SCHEMBL2885130 | 0.71 | NPC1 (0.42) | NPC1RAB9ASMN1; SMN2LMNAMAPT | |
| SCHEMBL6097616 | 0.71 | PDK2 (0.34) | — | |
| SCHEMBL3762000 | 0.69 | HPGDS (0.47) | NPC1RAB9ASMN1; SMN2LMNAMAPT | |
| SCHEMBL30352947 | 0.68 | CDK8 (0.54) | NPC1RAB9ASMN1; SMN2LMNAMAPT | |
| SCHEMBL5803268 | 0.68 | MEN1 (0.43) | NPC1RAB9ASMN1; SMN2LMNAMAPT | |
| SCHEMBL713218 | 0.66 | CYP1A2 (0.66) | NPC1RAB9ASMN1; SMN2LMNAMAPT | |
| SCHEMBL31325779 | 0.66 | CYP1A2 (0.66) | NPC1RAB9ASMN1; SMN2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490366-B1 | ALKOXYPYRIDINE-DERIVATIVES | NYCOMED GMBH (DE) | 2008-01-23 | — | — | EP | disclosed |
| US-7138399-B2 | 2-[2-(4-alkoxypyridin-2-yl)alkyl])-3H-imidazo[4,5-b]pyridine derivatives and 8-[2-(4-alkoxypyridin-2-yl)alkyl])-9H-purine derivatives; used to treat an acute inflammatory disease in which the activity of inducible NO-synthase is involved | ALTANA PHARMA AG (DE) | 2006-11-21 | — | — | US | disclosed |
| US-20050171125-A1 | 2-[2-(4-alkoxypyridin-2-yl)alkyl])-3H-imidazo[4,5-b]pyridine derivatives and 8-[2-(4-alkoxypyridin-2-yl)alkyl])-9H-purine derivatives; used to treat an acute inflammatory disease in which the activity of inducible NO-synthase is involved | ALTANA PHARMA AG (DE) | 2005-08-04 | — | — | US | disclosed |
| EP-1490366-A1 | NOVEL ALKOXYPYRIDINE-DERIVATIVES | ALTANA Pharma AG (DE) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003080607-A1 | NOVEL ALKOXYPYRIDINE-DERIVATIVES | ALTANA PHARMA AG (DE) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171125-A1 | 2-[2-(4-alkoxypyridin-2-yl)alkyl])-3H-imidazo[4,5-b]pyridine derivatives and 8-[2-(4-alkoxypyridin-2-yl)alkyl])-9H-purine derivatives; used to treat an acute inflammatory disease in which the activity of inducible NO-synthase is involved | NOS2, PNP, PTGIS | NPC1 3452/4885RAB9A 3706/4885SMN1; SMN2 3238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.